The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Vertex Pharmaceuticals (VRTX ... Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price ...

Vertex built its business treating ... Zai Lab (ZLAB) and Vertex Pharmaceuticals (VRTX) announced an exclusive collaboration and license agreement for the development and commercialization of ...

Mnwabisi Mbangata arrived at Vertex Pharmaceuticals almost two years ago with nearly ... From leading payer value proposition development for suzetrigine, a novel, non-opioid pain drug, to supporting ...

With a bulletproof CF business generating a mountain of cash, minimal competition on the horizon in this key area, and multiple shots at billion-dollar markets, Vertex offers a compelling mix of ...

Vertex built its business treating ... and Vertex Pharmaceuticals (VRTX) announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s ...